MBX Biosciences, Inc. Research and Development Expense
MBX Biosciences, Inc. (MBX) reported Research and Development Expense of $30.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- MBX Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $30.98M, a 74.82% increase year-over-year.
- MBX Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $18.47M, a 17.55% decline year-over-year.
- MBX Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $19.76M, a 29.80% increase year-over-year.
- MBX Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $19.27M, a 15.07% increase year-over-year.
- MBX Biosciences, Inc. research and development expense for fiscal 2025 was $79.16M, a 37.87% increase from fiscal 2024.
- MBX Biosciences, Inc. research and development expense for fiscal 2024 was $57.41M, a 101.22% increase from fiscal 2023.
- MBX Biosciences, Inc. research and development expense for fiscal 2023 was $28.53M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.98M 10-Q · filed 2026-08-06 | $49.46M 10-Q · filed 2026-08-06 | $69.22M derived: sum of 3 quarters · filed 2026-08-06 | $88.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.47M 10-Q · filed 2026-05-07 | $38.23M derived: sum of 2 quarters · filed 2026-05-07 | $57.50M derived: sum of 3 quarters · filed 2026-05-07 | $75.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $39.03M derived: sum of 2 quarters · filed 2026-03-12 | $56.75M derived: sum of 3 quarters · filed 2026-08-06 | $79.16M 10-K · filed 2026-03-12 |
| 2025-09-30 | $19.27M 10-Q · filed 2025-11-06 | $36.99M derived: sum of 2 quarters · filed 2026-08-06 | $59.40M 10-Q · filed 2025-11-06 | $74.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.72M 10-Q · filed 2026-08-06 | $40.13M 10-Q · filed 2026-08-06 | $55.35M derived: sum of 3 quarters · filed 2026-08-06 | $72.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $22.41M 10-Q · filed 2026-05-07 | $37.63M derived: sum of 2 quarters · filed 2026-05-07 | $54.38M derived: sum of 3 quarters · filed 2026-05-07 | $68.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $31.97M derived: sum of 2 quarters · filed 2026-03-12 | $46.37M derived: sum of 3 quarters · filed 2026-03-12 | $57.41M 10-K · filed 2026-03-12 |
| 2024-09-30 | $16.75M 10-Q · filed 2025-11-06 | $31.14M derived: sum of 2 quarters · filed 2025-11-06 | $42.19M 10-Q · filed 2025-11-06 | $49.92M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $14.40M 10-Q · filed 2025-08-07 | $25.45M 10-Q · filed 2025-08-07 | $33.17M derived: sum of 3 quarters · filed 2025-08-07 | $42.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $11.05M 10-Q · filed 2025-05-12 | $18.78M derived: sum of 2 quarters · filed 2025-05-12 | $27.85M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $7.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $16.80M derived: sum of 2 quarters · filed 2025-03-17 | $28.53M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $9.07M 10-Q · filed 2024-11-07 | $20.81M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |